Literature DB >> 9449047

Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.

S S Plymate1, V L Bae, L Maddison, L S Quinn, J L Ware.   

Abstract

The authors have previously shown that the type 1 insulin-like growth factor receptor (IGF-1R) is decreased in the transformation from benign to malignant human prostate epithelial cells in vivo. Further, in a well-described human SV40-T immortalized human epithelial cell system beginning with the immortalized, but rarely tumorigenic P69SV40-T cell line, to the highly tumorigenic and metastatic M12 subline, there is a similar decrease in IGF-1R number from 2.0 x 10(4) receptors per cell to 1.1 x 10(3) receptors per cell. When the IGF-1R was reexpressed in the M12 subline using a retroviral expression vector, M12-LISN, to a receptor number similar to that of the P69SV40-T parental cell line, the authors demonstrated a marked decrease in colony formation in soft agar in the M12-LISN cells vs the M12 control cells (p < or = 0.01), and a decrease in vivo tumor growth and metastases when injected either subcutaneously or an intraprostatic location (p < or = 0.01). This decrease in tumor volume was not because of a decrease in proliferative capacity, but was associated with an increase in apoptosis in baseline cultures and in response to the apoptotic-inducing agents 6-hydroxyurea, retinoic acid, and transforming growth factor beta 1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9449047     DOI: 10.1007/BF02778078

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  22 in total

1.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation.

Authors:  M Kaleko; W J Rutter; A D Miller
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

Review 2.  Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling?

Authors:  V A Blakesley; A Scrimgeour; D Esposito; D Le Roith
Journal:  Cytokine Growth Factor Rev       Date:  1996-08       Impact factor: 7.638

3.  Functional role of cation-independent mannose 6-phosphate/insulin-like growth factor II receptor in cell adhesion and proliferation of a human myeloma cell line OPM-2.

Authors:  T Nishiura; T Karasuno; H Yoshida; H Nakao; M Ogawa; Y Horikawa; M Yoshimura; Y Okajima; Y Kanakura; Y Kanayama; Y Matsuzawa
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

4.  Type-1 insulin-like growth factor receptor overexpression produces dual effects on myoblast proliferation and differentiation.

Authors:  L S Quinn; B Steinmetz; A Maas; L Ong; M Kaleko
Journal:  J Cell Physiol       Date:  1994-06       Impact factor: 6.384

5.  Identification and isolation of human epithelial cell colonies that express specific gene products.

Authors:  R E Gibson-D'Ambrosio; T Brady; S M D'Ambrosio
Journal:  Biotechniques       Date:  1995-11       Impact factor: 1.993

6.  Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways.

Authors:  M Párrizas; A R Saltiel; D LeRoith
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

7.  The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen.

Authors:  S R Plymate; M Tennant; R S Birnbaum; J B Thrasher; G Chatta; J L Ware
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

8.  Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium.

Authors:  M K Tennant; J B Thrasher; P A Twomey; R H Drivdahl; R S Birnbaum; S R Plymate
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

9.  Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor.

Authors:  V A Blakesley; T Kalebic; L J Helman; B Stannard; T N Faria; C T Roberts; D LeRoith
Journal:  Endocrinology       Date:  1996-02       Impact factor: 4.736

10.  Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression.

Authors:  V L Bae; C K Jackson-Cook; A R Brothman; S J Maygarden; J L Ware
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.396

View more
  5 in total

1.  An alternative, nonapoptotic form of programmed cell death.

Authors:  S Sperandio; I de Belle; D E Bredesen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.

Authors:  Mike Y Chen; Aaron J Clark; Dana C Chan; Joy L Ware; Shawn E Holt; Archana Chidambaram; Helen L Fillmore; William C Broaddus
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

3.  Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.

Authors:  A Chott; Z Sun; D Morganstern; J Pan; T Li; M Susani; I Mosberger; M P Upton; G J Bubley; S P Balk
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

4.  Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death.

Authors:  Mariana Pehar; Kenneth J O'Riordan; Melissa Burns-Cusato; Matthew E Andrzejewski; Carlos Gil del Alcazar; Corinna Burger; Heidi Scrable; Luigi Puglielli
Journal:  Aging Cell       Date:  2010-04       Impact factor: 9.304

5.  Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.

Authors:  Caterina Mancarella; Irene Casanova-Salas; Ana Calatrava; Maria García-Flores; Cecilia Garofalo; Andrea Grilli; José Rubio-Briones; Katia Scotlandi; José Antonio López-Guerrero
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.